IP Library Granted Patent US 12,426,937
Granted Patent B2
US 12,426,937 · App. 17/486,086 · Granted Sep 30, 2025

System and method for suppressing apoe gene for sarcoma treatment

Inventors: Jerome Canady (Lakeland, FL); Lawan Ly (Annadale, FL); Saravana R K Murthy (Owings, MD); Xiaoqian Cheng (Fairfax, VA); Taisen Zhuang (Rockville, MD)
Assignee: Jerome Canady Research Institute for Advanced Biological and Technological Sciences
A61B18/1206A61B5/7435A61B5/748A61B5/0033A61B5/0082A61B5/150335A61B2018/00005A61B2018/00077A61B2018/00583A61B2018/00636A61B2018/00642A61B2018/00779A61B2018/00964A61B2018/00988A61B18/02A61B18/1402A61B2560/0204A61B2560/0214A61B2562/0247
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,426,937
App. No.
17/486,086
Granted
Sep 30, 2025
Kind
B2
Abstract

A method for applying cold atmospheric plasma treatment to target tissue comprising the steps of treating a patient with a pharmaceutical for suppressing apolipoprotein E genes, selecting through a graphical user interface a particular soft tissue sarcoma cell line associated with target tissue, retrieving, with the computing device, settings data associated with the selected soft tissue sarcoma cell line from a database of cell line data and associated settings data in a storage, and applying, with the computing device, the retrieved settings data to a cold atmospheric plasma system.

Claims (16)

1. A method for treating cancer comprising:

treating a patient with a pharmaceutical for suppressing apolipoprotein E genes;

surgically resecting a liposarcoma from the patient; and

performing cold atmospheric plasma treatment on surgical margins of an area in the patient where the liposarcoma was resected after said patient is treated with the pharmaceutical for suppressing the apolipoprotein E genes.

2. A method for treating cancer according to claim 1 further comprising:

performing intraoperative radiation treatment on the patient during the surgical resection of the liposarcoma from the patent.

3. A method for treating cancer according to claim 1 wherein the cold atmospheric plasma treatment is performed for at least 7 minutes.

4. A method for treating cancer according to claim 3 wherein the cold atmospheric plasma treatment is performed for at least 7 minutes at a power setting of 120 W.

5. A method for applying cold atmospheric plasma treatment to target tissue comprising the steps of:

treating a patient with a pharmaceutical for suppressing apolipoprotein E genes;

surgically resecting a liposarcoma from the patient; and

after said patient is treated with the pharmaceutical for suppressing the apolipoprotein E genes, performing the following steps:

selecting through a graphical user interface a particular liposarcoma cell line associated with target tissue;

retrieving, with a computing device, settings data associated with said selected liposarcoma cell line from a database of cell line data and associated settings data in a storage;

applying, with said computing device, said retrieved settings data to a cold atmospheric plasma system; and

performing cold atmospheric plasma treatment on surgical margins of an area in the patient where the liposarcoma was resected.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2021
From: CANADY, JEROME, DR.; LY, LAWAN; MURTHY, SARAVANA; CHENG, XIAOQIAN; ZHUANG, TAISEN
To: JEROME CANADY RESEARCH INSTITUTE FOR ADVANCED BIOLOGICAL AND TECHNOLOGICAL SCIENCES
Reel/Frame 057762/0871 →
Continuity (2)
Provisional Application 63083621 · Sep 25, 2020
Related Publication 20220096140A1 · Mar 31, 2022
References Cited (44)
US 9999462B2 · Canady et al. · 2018 [cited by applicant]
US 10023858B2 · Canady et al. · 2018 [cited by applicant]
US 10213614B2 · Keidar et al. · 2019 [cited by applicant]
US 10405913B2 · Canady et al. · 2019 [cited by applicant]
US 10973564B2 · Canady · 2021 [cited by examiner]
US 10980591B2 · Canady et al. · 2021 [cited by applicant]
US 11020545B2 · Canady et al. · 2021 [cited by applicant]
US 20110212090A1 · Pedersen · 2011 [cited by examiner]
US 20140171854A1 · Jacofsky · 2014 [cited by examiner]
US 20140378892A1 · Guron et al. · 2014 [cited by applicant]
US 20160138006A1 · Canady · 2016 [cited by examiner]
US 20170183631A1 · Keidar · 2017 [cited by examiner]
US 20180117249A1 · Pennington · 2018 [cited by examiner]
US 20200237422A1 · Canady et al. · 2020 [cited by applicant]
US 20200261140A1 · Canady et al. · 2020 [cited by applicant]
US 20200384278A1 · Canady et al. · 2020 [cited by applicant]
US 20210015537A1 · Canady et al. · 2021 [cited by applicant]
TW 202122582A · 2021 [cited by examiner]
WO 2019199281A1 · 2019 [cited by applicant]
Ren L, Yi J, Li W, et al. Apolipoproteins and cancer. Cancer Med. 2019; 8: 7032-7043. (Year: 2019). [cited by examiner]
A. Fridman, Plasma Chemistry (Cambridge University Press, 2008). [cited by applicant]
E. Stoffels, Y. Sakiyama, and D.B. Graves “Cold Atmospheric Plasma: Charged Species and Their Interactions With Cells and Tissues” IEEE Trans. Plasma Sci. 36, 1441 (2008). [cited by applicant]
X. Lu, Y. Cao, P. Yang, Q. Xiong, Z. Xiong, Y. Xian, and Y. Pan “An RC Plasma Device for Sterilization of Root Canal of Teeth” IEEE Trans. Plasma Sci. 37, 668 (2009). [cited by applicant]
K.H. Becker, K.H. Shoenbach and J.G. Eden “Microplasma and applications” J. Phys. D.: Appl. Phys. 39, R55-R70 (2006). [cited by applicant]
E. Stoffels, I.E Kieft, R.E.J Sladek, L.J.M van den Bedem, E.P van der Laan, M. Steinbuch “Plasma needle for in vivo medical treatment: recent developments and perspectives” Plasma Sources Sci. Technol. 15, S169-S180 (2… [cited by applicant]
Yan D, Sherman J H and Keidar M, “Cold atmospheric plasma, a novel promising anti-cancer treatment modality,” Oncotarget. 8 15977-15995 (2017). [cited by applicant]
Keidar M, “Plasma for cancer treatment,” Plasma Sources Sci. Technol. 24 33001 (2015). [cited by applicant]
Hirst A M, Frame F M, Arya M, Maitland N J and O'Connell D, “Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future,” Tumor Biol. 37 7021-7031 (2016). [cited by applicant]
Keidar M, Walk R, Shashurin A, Srinivasan P, Sandler A, Dasgupta S, Ravi R, Guerrero-Preston R and Trink B, “Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy,” Br. J. Cancer. 105 1295-30… [cited by applicant]
Vandamme M, Robert E, Dozias S, Sobilo J, Lerondel S, Le Pape A and Pouvesle J-M, “Response of human glioma U87 xenografted on mice to non thermal plasma treatment,” Plasma Med. 1 27-43 (2011). [cited by applicant]
Brulle L, Vandamme M, Ries D, Martel E, Robert E, Lerondel S, Trichet V, Richard S, Pouvesle J M and Le Pape A, “Effects of a Non thermal plasma treatment alone or in combination with gemcitabine in a MIA PaCa2-Iuc orth… [cited by applicant]
Chernets N, Kurpad D S, Alexeev V, Rodrigues D B and Freeman T A, “Reaction chemistry generated by nanosecond pulsed dielectric barrier discharge treatment is responsible for the tumor eradication in the B16 melanoma mo… [cited by applicant]
Ahn H J, Kim K Il, Kim G, Moon E, Yang S S and Lee J S, “Atmospheric-pressure plasma jet induces apoptosis involving mitochondria via generation of free radicals,”. PLoS One. 6 e28154 (2011). [cited by applicant]
Ja Kim S, Min Joh H and Chung T H, “Atmospheric-pressure plasma jet induces apoptosis and change of cell viability induced by atmospheric pressure plasma in normal and cancer cells,” Appl. Phys. Lett. 103 153705 (2013). [cited by applicant]
Yan D, Talbot A, Nourmohammadi N, Sherman J H, Cheng X and Keidar M, “Toward understanding the selective anticancer capacity of cold atmospheric plasma—a model based on aquaporins (Review),” Biointerphases. 10 040801 (2… [cited by applicant]
Yan D, Xiao H, Zhu W, Nourmohammadi N, Zhang L G, Bian K and Keidar M, “The role of aquaporins in the anti-glioblastoma capacity of the cold plasma-stimulated medium,” J. Phys. D. Appl. Phys. 50 055401 (2017). [cited by applicant]
Yan D, Talbot A, Nourmohammadi N, Cheng X, Canady J, Sherman J and Keidar M, “Principles of using cold atmospheric plasma stimulated media for cancer treatment,” Sci. Rep. 5 18339 (2015). [cited by applicant]
Ma Y, Ha C S, Hwang S W, Lee H J, Kim G C, Lee K W and Song K, “Non-thermal atmospheric pressure plasma preferentially induces apoptosis in p53-mutated cancer cells by activating ROS stress-response pathways,” PLoS One.… [cited by applicant]
Sablina A A, Budanov A V, Ilyinskaya G V, Larissa S, Kravchenko J E and Chumakov P M, “The antioxidant function of the p53 tumor suppressor,” Nat. Med. 11 1306 (2005). [cited by applicant]
Maillet A and Pervaiz S, “Redox regulation of p53, redox effectors regulated by p53: a subtle balance,” Antioxid. Redox Signal. 16 1285-1294 (2012). [cited by applicant]
Naciri M, Dowling D and Al-Rubeai M, “Differential sensitivity of mammalian cell lines to non-thermal atmospheric plasma,” Plasma Process. Polym. 11 391-400 (2014). [cited by applicant]
Fearon E F and Vogelstein B, “A genetic model for colorectal tumorigenesis,” Cell. 61 759-767 (1990). [cited by applicant]
Yan D, Cui H, Zhu W, Nourmohammadi N, Milberg J, Zhang L G, Sherman J H and Keidar M, “The specific vulnerabilities of cancer cells to the cold atmospheric plasma-stimulated solutions,” Sci. Rep. 7 4479 (2017). [cited by applicant]
G.Fridman, G. Friedman, A. Gutsol, A. B. Shekhter, V. N. Vasilets, and A. Fridman “Applied Plasma Medicine”, Plasma Processes Polym. 5, 503 (2008). [cited by applicant]